MGX compared with CATO: revenue, margins and what each company keeps, and the suppliers and customers both name

MGXMetagenomi Therapeutics, Inc.

Mkt capRevenueRevenue

CATOCato Corp

Mkt capRevenueRevenue

Compare

MGXMetagenomi Therapeutics, Inc.

CATOCato Corp

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

MGX1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▼−1.63%—

CATO1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±17.4%0.00%×0.00

= impliedMGX realized, solidCATO realized, hatchedOne scale, both sides: full bar = 18%× = |realized| ÷ impliedSource: market data

MGXMetagenomi Therapeutics, Inc.

0.76▲+0.79%· post 0.76

Mkt cap$29.5MRevenue$1MQ1 FY26Revenue$25MFY25

CATOCato Corp

2.310.00%

ClosedNov 3 '26

Mkt cap$46.4MRevenue$166MQ2 FY26Revenue$654MFY25

Compare

ClosedNov 3 '26

MGXMetagenomi Therapeutics, Inc.

CATOCato Corp

0.76▲+0.79%post 0.76

Price

2.310.00%

$29.5M

Mkt cap

$46.4M

Q1 FY26$1M

Revenue

$166MQ2 FY26

FY25$25M

Revenue

$654MFY25

MGX0.76▲+0.79%vsCATO2.310.00%ClosedNov 3 '26